Physician profile
Jeromy Todd Hackney
NPI 1225263817
$8,363.99
in general payments reported to CMS, 2019-2025
36 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $561 · 2021: $612 · 2022: $1,548 · 2023: $1,614 · 2024: $1,775 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,703.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $913.07 | 2021-2024 | Axonics, Bulkamid |
| Boston Scientific Corporation | $869.62 | 2019-2025 | Axonics, Rezum Generator, Solyx Sis System |
| Medtronic, INC. | $817.35 | 2021-2025 | Interstim |
| Astellas Pharma US INC | $784.22 | 2019-2024 | Myrbetriq, Xtandi |
| Teleflex LLC | $628.48 | 2021-2025 | Urolift, Barrigel |
| Coloplast Corp | $571.03 | 2019-2024 | Titan |
| Endo Pharmaceuticals INC. | $444.39 | 2019-2023 | Aveed, Xiaflex |
| Medtronic USA, INC. | $344.62 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $312.99 | 2023-2025 | Gemtesa, Orgovyx |
| Myriad Genetic Laboratories, INC. | $307.52 | 2021-2024 | Prolaris, Bracanalysis Cdx |
| C. R. Bard, INC. & Subsidiaries | $277.47 | 2019-2025 | |
| Intuitive Surgical, INC. | $275.25 | 2019-2024 | |
| Pfizer INC. | $227.78 | 2019-2025 | |
| Antares Pharma, INC. | $196.07 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Neotract INC. | $171.52 | 2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $142.32 | 2019-2025 | Adstiladrin |
| Endo USA, INC. | $132.71 | 2024-2025 | Xiaflex, Aveed |
| Merck Sharp & Dohme LLC | $130.50 | 2022-2024 | Keytruda, Welireg, Lenvima |
| Urovant Sciences INC | $111.61 | 2021-2022 | |
| Angiodynamics, INC. | $104.14 | 2024 | Nanoknife |
| Olympus America INC. | $98.27 | 2019-2025 | Itind System, Bovie |
| Procept Biorobotics Corporation | $90.07 | 2022-2024 | Aquabeam System |
| Halozyme INC | $72.93 | 2023 | |
| Urogen Pharma, INC. | $46.65 | 2022-2023 | Jelmyto |
| Abbvie INC. | $43.75 | 2022-2023 | |
| 180 Medical, INC. | $40.27 | 2023-2024 | |
| Argon Medical Devices, INC. | $31.68 | 2024 | Clot Management |
| Bayer Healthcare Pharmaceuticals INC. | $29.93 | 2025 | |
| Myovant Sciences INC. | $29.69 | 2022 | |
| Avanos Medical | $25.71 | 2020 | |
| Convatec INC. | $20.34 | 2019 | |
| Laborie Medical Technologies Corp. | $17.94 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Civco Medical Instruments | $17.00 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.09 | 2023 | Seglentis |
| Travere Therapeutics, INC. | $12.31 | 2022 | |
| Ethicon US, LLC | $11.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeromy Hackney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.